Making anti-cytokine therapy more selective: Studies in mice

被引:11
|
作者
Drutskaya, Marina S. [1 ]
Efimov, Grigory A. [1 ,2 ,3 ]
Astrakhantseva, Irina V. [3 ]
Kruglov, Andrei A. [1 ,3 ,4 ,5 ]
Nedospasov, Sergei A. [1 ,3 ,4 ,5 ]
机构
[1] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia
[2] Natl Sci Ctr Hematol, Moscow 125167, Russia
[3] Lobachevsky State Univ Nizhny Novgorod, Nizhnii Novgorod 603950, Russia
[4] Lomonosov Moscow State Univ, Moscow 199991, Russia
[5] German Rheumatism Res Ctr DRFZ, D-10117 Berlin, Germany
基金
俄罗斯科学基金会;
关键词
Anti-cytokine therapy; Autoimmunity and inflammation; MYSTI; TUMOR-NECROSIS-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RHEUMATOID-ARTHRITIS; FACTOR RECEPTOR; PROINFLAMMATORY CYTOKINE; INFLAMMATORY ARTHRITIS; STERILE INFLAMMATION; TNF RECEPTOR; FACTOR-ALPHA; IN-VIVO;
D O I
10.1016/j.cyto.2016.08.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytokines are involved in a wide range of functions shaping the normal immune response, yet inflammatory changes in the immune system due to dysregulated cytokine signaling may lead to the induction of autoimmunity. Cytokine inhibitors have revolutionized the treatment of many autoimmune diseases in recent years. Systemic cytokine ablation, however, is often associated with the development of adverse side effects and some patients simply do not respond to therapy. TNF, IL-1 and IL-6 are the best characterized proinflammatory cytokines considered as the main therapeutic targets for the treatment of several autoimmune and inflammatory diseases. But can anti-cytokine therapy become more selective and thus more efficient? This mini-review discusses several recently emerging paradigms and summarizes current experimental attempts to validate them in mouse studies. (C) 2016 Published by Elsevier Ltd.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 50 条
  • [41] Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy
    Knyazev, Oleg, V
    Khomeriki, Sergey G.
    Kagramanova, Anna, V
    Lishchinskaya, Albina A.
    Smirnova, Olga A.
    Noskova, Karina K.
    Parfenov, Asfold, I
    TERAPEVTICHESKII ARKHIV, 2021, 93 (12) : 1435 - 1442
  • [43] Anti-cytokine therapy for the treatment of graft-versus-host disease
    Jacobsohn, DA
    Vogelsang, GB
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (11) : 1195 - 1205
  • [44] Therapeutic applications of anti-cytokine strategies
    S Poole
    Molecular Psychiatry, 1997, 2 : 137 - 138
  • [45] Anti-cytokine antibodies for rheumatic diseases
    Atzeni, Fabiola
    Sarzi-Puttini, Piercarlo
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (11) : 1204 - 1211
  • [46] Anti-cytokine autoantibodies in autoimmune diseases
    Cappellano, Giuseppe
    Orilieri, Elisabetta
    Woldetsadik, Abiy D.
    Boggio, Elena
    Soluri, Maria F.
    Comi, Cristoforo
    Sblattero, Daniele
    Chiocchetti, Annalisa
    Dianzani, Umberto
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 1 (02): : 136 - 146
  • [47] Anti-cytokine autoantibodies in postherpetic neuralgia
    Ahmad Bayat
    Peter D. Burbelo
    Sarah K. Browne
    Mark Quinlivan
    Bianca Martinez
    Steven M. Holland
    Asokumar Buvanendran
    Jeffrey S. Kroin
    Andrew J. Mannes
    Judith Breuer
    Jeffrey I. Cohen
    Michael J. Iadarola
    Journal of Translational Medicine, 13
  • [48] Targeted anti-cytokine therapies for osteoarthritis
    Chevalier, Xavier
    Mugnier, Benedicte
    Bouvenot, Gilles
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2006, 190 (07): : 1411 - 1420
  • [49] Anti-cytokine vaccination in autoimmune diseases
    Delavallee, Laure
    Duvallet, Emilie
    Semerano, Luca
    Assier, Eric
    Boissier, Marie-Christophe
    SWISS MEDICAL WEEKLY, 2010, 140 : 28 - 32
  • [50] Cytokine and anti-cytokine therapies for inflammatory bowel disease
    Ogata, H
    Hibi, T
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (14) : 1107 - 1113